JINYU(SH:600201)2021-10-28 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥497,962,981.50, representing a year-on-year increase of 3.02%[7] - The net profit attributable to shareholders for Q3 2021 was ¥160,678,332.58, reflecting a significant increase of 41.83% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥136,438,700.63, up by 23.43% year-on-year[11] - The basic earnings per share for Q3 2021 was ¥0.14, an increase of 40.00% compared to the same period last year[11] - Net profit for the first three quarters of 2021 was ¥454,201,985.59, compared to ¥349,815,780.97 in the same period of 2020, indicating a growth of 29.8%[39] - The net profit attributable to the parent company's shareholders was CNY 418,621,189.85, an increase from CNY 295,732,932.28, representing a growth of approximately 41.5% year-over-year[41] - The total comprehensive income attributable to the parent company's shareholders reached CNY 418,898,934.30, compared to CNY 295,938,327.05 in the previous year, indicating a year-over-year increase of about 41.5%[44] - Basic and diluted earnings per share were both CNY 0.37, up from CNY 0.26 in the same period last year, reflecting a growth of approximately 42.3%[44] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,555,290,017.34, which is a 4.41% increase from the end of the previous year[11] - The equity attributable to shareholders at the end of the reporting period was ¥5,288,932,827.82, up by 6.17% year-on-year[11] - Total assets as of Q3 2021 amounted to ¥6,555,290,017.34, an increase from ¥6,278,282,683.24 in Q3 2020, representing a growth of 4.4%[35] - Total liabilities decreased to ¥977,639,614.26 in Q3 2021 from ¥1,015,342,820.46 in Q3 2020, a reduction of 3.7%[35] - The company's total current assets amounted to RMB 3,143,308,830.04, a decrease of 1.37% from RMB 3,187,018,741.38 on December 31, 2020[29] - The company's total liabilities as of September 30, 2021, are not explicitly stated but are essential for assessing financial health[29] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥257,770,973.41, showing a decrease of 36.18% compared to the previous year[11] - Cash inflow from operating activities totaled CNY 1,194,933,674.77, slightly up from CNY 1,193,422,788.19, showing a marginal increase of 0.13%[44] - The net cash flow from operating activities was CNY 257,770,973.41, down from CNY 403,880,298.08, indicating a decrease of approximately 36.2% year-over-year[47] - The company reported cash inflow from investment activities of CNY 451,631,093.82, compared to CNY 539,714,796.79 in the previous year, reflecting a decline of about 16.3%[47] - The net cash flow from investment activities was negative at CNY -19,687,162.99, a significant improvement from CNY -450,222,980.92 in the previous year[47] - The total cash and cash equivalents at the end of the period were CNY 1,440,193,503.87, up from CNY 833,261,932.89, representing an increase of approximately 73%[47] - The company received CNY 13,117,786.50 from financing activities, while cash outflow for financing activities was CNY 131,986,784.80, leading to a net cash flow of CNY -118,868,998.30[47] Shareholder Information - The company had a total of 60,708 common shareholders at the end of the reporting period[18] - The largest shareholder, Hong Kong Central Clearing Limited, held 11.43% of the shares, while Inner Mongolia Jinyu Biological Holdings Limited held 10.86%[18] Inventory and Investments - The company's inventory decreased to RMB 320,408,173.56 from RMB 350,661,798.80, a reduction of 8.6%[29] - The company’s long-term equity investments slightly decreased to RMB 263,641,045.75 from RMB 266,722,496.16, a decline of 1.1%[29] - The company’s fixed assets decreased to RMB 1,636,586,113.04 from RMB 1,698,893,578.48, reflecting a decline of 3.7%[29] Research and Development - Research and development expenses increased to ¥96,347,351.37 in Q3 2021, compared to ¥84,962,776.40 in Q3 2020, marking a rise of 13.5%[38] Other Developments - The company plans to raise up to RMB 900 million through a non-public offering of A-shares, with a maximum issuance of 63,157,895 shares at a price of RMB 14.25 per share[25] - The company’s subsidiary has received a new veterinary drug registration certificate for its recombinant vaccines, indicating progress in product development[25]